Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) Invested Capital (2016 - 2025)

Neuroone Medical Technologies' Invested Capital history spans 14 years, with the latest figure at $6.4 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 118.1% year-over-year to $6.4 million; the TTM value through Dec 2025 reached $6.4 million, up 118.1%, while the annual FY2025 figure was $7.1 million, 760.39% up from the prior year.
  • Invested Capital reached $6.4 million in Q4 2025 per NMTC's latest filing, down from $7.1 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $15.9 million in Q4 2021 to a low of $822013.0 in Q3 2024.
  • Average Invested Capital over 5 years is $6.9 million, with a median of $6.5 million recorded in 2021.
  • Peak YoY movement for Invested Capital: soared 1032.53% in 2021, then tumbled 87.11% in 2024.
  • A 5-year view of Invested Capital shows it stood at $15.9 million in 2021, then crashed by 48.76% to $8.2 million in 2022, then crashed by 45.93% to $4.4 million in 2023, then crashed by 33.56% to $2.9 million in 2024, then skyrocketed by 118.1% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Invested Capital are $6.4 million (Q4 2025), $7.1 million (Q3 2025), and $8.2 million (Q2 2025).